The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Astellas Pharma; Bayer; Johnson & Johnson; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - Bayer; Johnson & Johnson
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Johnson & Johnson; Pfizer
 
Research Funding - Aptevo Therapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst)
Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Churchill Pharmaceuticals; EMD Serono; Incyte; Janssen; Merck; QED Therapeutics; Tolmar
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen (Inst)
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Genentech; Ipsen; Janssen; Lilly; MedImmune
Other Relationship - Abbvie; Agios; Amgen; AMO Pharma; arGEN-X BVBA
 
Margitta Retz
No Relationships to Disclose
 
Ali Tafreshi
No Relationships to Disclose
 
Joan Carles Galceran
No Relationships to Disclose
 
Peter Hammerer
Consulting or Advisory Role - Bayer; Janssen; Sanofi
 
Peter C.C. Fong
Honoraria - AstraZeneca; Merck Sharp & Dohme
Consulting or Advisory Role - Merck Sharp & Dohme
Speakers' Bureau - Janssen
Travel, Accommodations, Expenses - Pfizer
 
Neal D. Shore
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Anthony Joshua
No Relationships to Disclose
 
Mark David Linch
Consulting or Advisory Role - BioNTech; Bristol-Myers Squibb; Janssen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck
 
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
 
Emanuela Romano
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Marinela Augustin
Consulting or Advisory Role - IPSEN; Lilly; Novartis; Pfizer; PharmaMar; Roche
Travel, Accommodations, Expenses - Ipsen; Lilly; Novartis; PharmaMar
 
Josep M. Piulats
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck Sharp & Dohme; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Janssen Oncology; Merck Sharp & Dohme; Pfizer/EMD Serono
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; Roche
 
Haiyan Wu
Employment - MSD
Stock and Other Ownership Interests - Bayer (I); MSD (I)
 
Charles Schloss
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Christian Heinrich Poehlein
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex